Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18520984rdf:typepubmed:Citationlld:pubmed
pubmed-article:18520984lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18520984lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18520984lifeskim:mentionsumls-concept:C0018546lld:lifeskim
pubmed-article:18520984lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:18520984lifeskim:mentionsumls-concept:C0299792lld:lifeskim
pubmed-article:18520984lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:18520984pubmed:issue3lld:pubmed
pubmed-article:18520984pubmed:dateCreated2008-6-3lld:pubmed
pubmed-article:18520984pubmed:abstractTextSchizophrenia is a chronic disease that is treated with dopamine antagonists. These drugs can produce intolerable side effects through their blockade of central nervous system dopamine receptors unrelated to schizophrenia. The atypical antipsychotic aripiprazole, a dopamine receptor partial agonist, has mixed agonist-antagonist effects. Its partial agonism is said to protect the patient from the side effects caused by full antagonists at the same time that its antagonism treats the schizophrenia effectively.lld:pubmed
pubmed-article:18520984pubmed:languageenglld:pubmed
pubmed-article:18520984pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18520984pubmed:citationSubsetIMlld:pubmed
pubmed-article:18520984pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18520984pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18520984pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18520984pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18520984pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18520984pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18520984pubmed:statusMEDLINElld:pubmed
pubmed-article:18520984pubmed:issn1537-162Xlld:pubmed
pubmed-article:18520984pubmed:authorpubmed-author:HwuHai-GwoHGlld:pubmed
pubmed-article:18520984pubmed:authorpubmed-author:KuoJosephJlld:pubmed
pubmed-article:18520984pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18520984pubmed:volume31lld:pubmed
pubmed-article:18520984pubmed:ownerNLMlld:pubmed
pubmed-article:18520984pubmed:authorsCompleteYlld:pubmed
pubmed-article:18520984pubmed:pagination173-5lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:meshHeadingpubmed-meshheading:18520984...lld:pubmed
pubmed-article:18520984pubmed:articleTitleAripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.lld:pubmed
pubmed-article:18520984pubmed:affiliationDepartment of Psychiatry, Lotung St. Mary's Hospital, Ilan, Taiwan. kuo2084@yahoo.com.twlld:pubmed
pubmed-article:18520984pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18520984pubmed:publicationTypeCase Reportslld:pubmed